BISSOT'D · Biochemical and Structural characterization of signal transduction by OTU family of Deubiquitinases
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2010-04-01 → 2012-03-31
- Финансиране от ЕС
- 180 103 €
- Участници
- 1
- Схема
- MC-IEF
Линиите свързват координатора с партньорите.
Накратко на български
Ензимите от фамилията OTU разграждат специфични протеинови вериги, като например Cezanne се фокусира върху K11 връзките. Разбирането на този механизъм помага да се разбере как се регулират клетъчните сигнали, имунните отговори и генната експресия.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Biochemical and structural characterisation of signal transduction by OTU family of Deubiquitinases
Ubiquitination is a reversible protein modification that regulates diverse cellular functions including cell signalling, cell cycle, immune responses and gene expression. 8 differently linked polyubiquitin chains can be assembled using either 1 of the 7 lysine residues or Met1 in ubiquitin. Each linkage type adopts a distinct conformation and hence enzymes and ubiquitin binding domains have evolved ways to distinguish between different ubiquitin chain types and thereby achieve specificity. Protein ubiquitination is negatively regulated by specialised proteases called Deubiquitinases (DUBs) that reverse protein ubiquitination by hydrolysing the isopeptide linkage between ubiquitin moieties in ubiquitin chains or between ubiquitin and protein substrates. The ovarian tumour proteases (OTU) form a family of cysteine-based proteases and within the OTU family are the A20-like OTU DUBs consisting of A20, Cezanne1 and 2, VCIP135 and TRABID that have been shown to regulate ubiquitin signalling. Since there is no crystal structure of a cysteine protease in complex with a diubiquitin substrate, the exact catalytic mechanism employed is unclear. While A20 negatively regulates NF-kB signalling by removing K63-linked ubiquitin chains in cells, this OTU only cleaves K48-linked chains in vitro. Other members such as Cezanne1 and 2 show remarkable specificity towards K11 linkages, while TRABID hydrolyses K29 and K33 chains. Since Cezanne is highly selective for K11 linkages, we reasoned that obtaining a crystal structure of Cezanne in complex with K11-linked diubiquitin will provide insights into how substrate specificity is achieved. As a starting point, we solved the structure of the catalytic domain of Cezanne and this showed that it has a fold similar to that of the other A20-family OTUs. We then crystallised enzyme-product intermediate complexes by crystallising Cezanne in complex with ubiquitin. This structure reveals the distal ubiquitin binding site in Cezanne, which is distinct from that of other OTUs. We could confirm that the mode of distal ubiquitin binding is also similar in A20 by solving the structure of an A20~ubiquitin complex. Comparing the apo and ubiquitin complex structures of Cezanne revealed that conformational changes take place to remodel the DUB from a closed catalytically incompetent conformation to an open active conformation where a proximal ubiquitin-binding site is created. Moreover, the different structures reveal that the catalytic centre of Cezanne is held in an inactive conformation in the resting state and can be remodelled to an active state upon ubiquitin binding. By comparing the structures of A20 with that of TRABID and Cezane, we identified the existence of a loop in the catalytic domain of A20, which drives activity and specificity of A20. Based on our observations we hypothesise that this loop must be remodelled in order to activate the protease activity of A20. Further, we could show that the catalytic cysteine of A20 is regulated by reactive oxygen species (ROS) and this is a reversible regulation analogous to that observed in phosphatases. In summary, these findings reveal novel regulatory mechanisms modulating the activity of A20 and A20 family of OTU DUBs.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Ubiquitination is a reversible post-translational modification (PTM) regulating diverse cellular functions including cell cycle, apoptosis, gene expression, inflammation and DNA repair. Ubiquitination results in the tagging of proteins with either monoubiquitin or polyubiquitin chains of different linkages that are structurally distinct. Given that protein ubiquitination is involved in so many cellular processes, it needs to be under very tight regulation. Protein ubiquitination is reversed by deubiquitinases (DUBs), which are specialized proteases that cleave the isopeptide linkage between ubiquitin molecules in chains or between ubiquitin and protein substrates. The objective of this study is to understand how substrate specificity is determined and in particular, how function of the A20-family of ovarian tumour (OTU) DUBs is regulated. I will crystallize the catalytic domains of OTU family DUBs involved in cell signalling, to understand their ubiquitin chain linkage specificity. I intend to establish how the interacting scaffolding proteins of A20-like DUBs, such as ABIN and TAX1BP1, mediate substrate targeting and specificity, and allosterically regulate enzyme activity. I shall express full-length protein complexes of A20 and Cezanne together with their interacting proteins using multi-gene baculovirus and mammalian systems. I will use X-ray crystallography and electron microscopy to understand the structure and conformational changes regulating DUB complex activation. The structural insights obtained will be used to understand oncogenic DUB mutants, and establish how DUB dysregulation leads to tumorigenesis. Lastly, I will analyze how reversible oxidation regulates DUBs during signalling. The proposed structural and biochemical characterisation of the multi-subunit protein complexes of DUBs will help define the molecular details of allosteric mechanisms governing A20-like DUBs and provide the basis for design of pharmaceutical modulators of DUB activity.
Оригинален текст от CORDIS (на английски).
Участници
- MEDICAL RESEARCH COUNCIL · LONDONКоординаторОбединеното кралство
Връзки
Данни: CORDIS, © Европейски съюз
